Exicure, Inc

(NASDAQ:XCUR)

Latest On Exicure, Inc (XCUR):

Date/Time Type Description Signal Details
2023-05-26 18:27 ESTNewsExicure board backs CEO Kim's strategic alternative view for companyN/A
2023-05-19 17:06 ESTNewsExicure gets Nasdaq non-compliance notice for not filing 10-QN/A
2023-05-04 18:26 ESTNewsExicure buys $1M convertible bonds issued by Cyworld ZN/A
2023-04-27 11:51 ESTNewsExicure gets new CEO and CFO replacementN/A
2023-03-27 22:36 ESTNewsExicure GAAP EPS of -$0.56, revenue of $28.83MN/A
2022-12-14 07:42 ESTNewsExicure says development collaborations with AbbVie, Ipsen terminatedN/A
2022-11-15 10:06 ESTNewsExicure GAAP EPS of -$1.04, revenue of $2MN/A
2022-09-27 03:15 ESTNewsExicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activitiesN/A
2022-08-15 23:49 ESTNewsExicure Q2 GAAP loss per share narrows, revenue upN/A
2022-07-21 04:22 ESTNewsExicure regains compliance with Nasdaq's minimum bid price requirementN/A
2022-06-30 01:39 ESTNewsExicure slides 31% as it implements reverse-stock-split to get back Nasdaq complianceN/A
2022-05-21 23:36 ESTNewsExicure up 27% pre market following insider buyN/A
2022-05-16 22:52 ESTNewsExicure GAAP EPS of -$0.07, revenue of $2.57MN/A
2022-05-11 12:48 ESTNewsExicure rallies 41% on announcement to raise $5M in private stock offeringN/A
2022-03-26 16:14 ESTNewsExicure GAAP EPS of -$0.72N/A
2022-03-26 16:13 ESTNewsExicure stock sinks postmarket on weak results, going concern riskN/A
2021-12-15 00:30 ESTNewsExicure to raise $11.5M in registered direct offeringN/A
2021-11-19 22:37 ESTNewsExicure EPS misses by $0.17, misses on revenueN/A
2021-11-17 06:19 ESTNewsExicure files Form 12b-25 for delay in filing quarterly reportN/A
2021-10-06 21:33 ESTNewsXCUR is at high risk of performing badlyN/A
2021-09-28 05:22 ESTNewsWarning: XCUR has been downgraded to Very BearishN/A
2021-09-22 11:23 ESTNewsWarning: XCUR has been downgraded to Very Bearish.N/A
2021-09-11 06:29 ESTNewsExicure (XCUR) Corporate OverviewN/A
2021-08-03 02:27 ESTNewsExicure soars 38% on collaboration with Ipsen targeting rare neurodegenerative disorders (updated)N/A
2021-03-23 12:54 ESTNewsRevisiting The Investment Thesis On ExicureN/A
2021-03-14 09:55 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 08:50 ESTEarnings EstimateAn EPS average of -$0.70 is estimated for the 2022 year.Sell
2021-03-12 08:50 ESTEarnings EstimateAn EPS average of -$0.10 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 17:06 ESTNewsExicure EPS misses by $0.02, misses on revenueN/A
2021-03-03 16:42 ESTNewsExicure's cavrotolimod an Orphan Drug in U.S. for rare skin cancerN/A
2021-01-11 10:00 ESTNewsExicure's cavrotolimod Fast Track'd in U.S. for skin cancerN/A
2020-12-25 09:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.75 to $10.Neutral
2020-12-24 09:21 ESTAnalyst RatingThe Analyst Target Price has increased from $10 to $10.75.Buy
2020-12-21 17:25 ESTNewsExicure announces issuance of two new U.S. patents, and new patent allowanceN/A
2020-12-21 05:40 ESTAnalyst RatingThe Analyst Target Price has decreased from $11 to $10.Neutral
2020-11-26 22:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 23:34 ESTNewsExicure (XCUR) Investor Presentation - SlideshowN/A
2020-11-17 05:45 ESTAnalyst RatingThe Analyst Target Price has increased from $10.5 to $11.Buy
2020-11-14 13:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:45 ESTEarnings EstimateAn EPS average of -$0.11 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-12 08:52 ESTNewsExicure EPS misses by $0.01, beats on revenueN/A
2020-11-08 01:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:37 ESTFinancialsCompany financials have been released.Neutral
2020-10-02 04:04 ESTNewsExicure secures up to $25M in debt financingN/A
2020-09-26 14:37 ESTFinancialsCompany financials have been released.Neutral
2020-09-18 18:47 ESTAnalyst RatingThe Analyst Target Price has increased from $10 to $10.5.Buy
2020-09-17 10:08 ESTNewsExicure's cavrotolimod shows encouraging action in early-stage solid tumor studyN/A
2020-09-17 06:42 ESTFinancialsCompany financials have been released.Neutral
2020-09-12 18:16 ESTNewsStocks To Watch: Apple, Snowflake, Pfizer And Moderna In FocusN/A
2020-08-15 05:57 ESTFinancialsCompany financials have been released.Neutral

About Exicure, Inc (XCUR):

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

XCUR Quotes by TradingView

See Advanced Chart

General

  • Name Exicure, Inc
  • Symbol XCUR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 63
  • Fiscal Year EndDecember
  • IPO Date2018-05-22
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.exicuretx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 13.33
  • Price/Book (Most Recent Quarter) 3.63
  • Enterprise Value Revenue 10
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.51
  • Next Year EPS Estimate -$0.66
  • Next Quarter EPS Estimate -$0.11
  • Profit Margin -148%
  • Operating Margin -153%
  • Return on Assets -15%
  • Return on Equity -35%
  • Revenue 16.61 million
  • Earnings Per Share -$0.47
  • Revenue Per Share $0.19
  • Gross Profit -15481000
  • Quarterly Earnings Growth -54.8%
View More

Highlights

  • Market Capitalization 207.59 million
  • EBITDA -20937000
  • PE Ratio 1.4
  • Analyst Target Price $10
  • Book Value Per Share $0.70
View More

Share Statistics

  • Shares Outstanding 87.96 million
  • Shares Float 64.37 million
  • % Held by Insiders 2333%
  • % Held by Institutions 46.17%
  • Shares Short 1.36 million
  • Shares Short Prior Month 1.34 million
  • Short Ratio 2.53
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.38
  • 52 Week High $3.19
  • 52 Week Low $0.96
  • 50 Day Moving Average 2.35
  • 200 Day Moving Average 1.94
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Exicure, Inc (XCUR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Exicure, Inc (XCUR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.15-$0.12-27.66%
2020-09-302020-11-12$2.44 million-$0.10-$0.09-8.11%
2020-06-302020-08-12$N/A-$0.05-$0.0941.18%
2020-03-312020-05-14$9.18 million$0.01-$0.09111.11%
2019-12-312020-03-03$310000-$0.14-$0.09-60%
2019-09-302019-11-07$527000-$0.09-$0.08-12.5%
2019-06-302019-08-08$434000-$0.12-$0.137.69%
2019-03-312019-05-08$25000-$0.12-$0.120%
2018-12-312019-03-08$6000-$0.10-$0.1533.33%
2018-09-302018-11-06$57000-$0.13-$0.1618.75%
2018-06-302018-08-06$19000-$0.17-$0.15-13.33%
2018-03-312018-05-15$36000-$0.14

Exicure, Inc (XCUR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A 9.14 million N/A 6.08 million N/A
Income Before Tax N/A -8.82 million N/A 1.15 million -9.98 million
Selling General Administrative N/A 2.42 million N/A 2.57 million 2.15 million
Gross Profit N/A N/A N/A N/A -7.96 million
Ebit N/A -8.12 million N/A 1.43 million -10.11 million
Operating Income N/A -9.12 million N/A 534000 -10.11 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A 2.44 million N/A 9.18 million 310000
Cost of Revenue N/A N/A N/A N/A 8.27 million
Total Other Income Expense Net N/A 120000 N/A 384000 128000
Net Income From Continuing Operations N/A -8.82 million N/A 1.15 million -9.98 million
Net Income Applicable to Common Shares -12.69 million N/A -4.31 million N/A -9.98 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 5.64 million 3.54 million -12.5 million N/A N/A
Change to Liabilities N/A -6.62 million N/A N/A -312000
Total Cash Flow from Investing Activities N/A 3.54 million N/A N/A -400000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 17.28 million 50000 -2.33 million N/A 58.63 million
Change to Operating Activities N/A -1.24 million N/A N/A 311000
Change in Cash 14.26 million -7.38 million -22.68 million N/A 53.22 million
Total Cash from Operating Activities -8.65 million -10.97 million -7.85 million N/A -5.02 million
Depreciation 677000 187000 148000 N/A 340000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A -4.62 million
Change to Net Income N/A 1.01 million N/A N/A 407000
Capital Expenditures 78000 2.42 million 577000 N/A 400000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 38.94 million 37.85 million N/A 20.42 million 34.52 million
Total Stockholder Equity 61.51 million 73.43 million N/A 85.11 million 80.75 million
Other Current Liabilities 8.34 million 71000 N/A N/A 21.87 million
Total Assets 100.44 million 111.28 million N/A 105.53 million 115.26 million
Common Stock 9000 N/A 9000 N/A 9000
Other Current Assets 4.23 million 1 million N/A 920000 N/A
Retained Earnings -105.97 million -93.28 million -84.46 million -80.15 million -81.3 million
Other Liabilities 656000 N/A N/A N/A 3.37 million
Other Assets 1.39 million N/A 2.27 million N/A 388000
Cash 33.26 million 31.46 million N/A 24.58 million 48.46 million
Total Current Liabilities 13.73 million 12.61 million N/A 20.37 million 31.09 million
Other Stockholder Equity 83000 N/A 338000 N/A -27000
Property, Plant & Equipment 4.12 million N/A 4.46 million N/A 2.1 million
Total Current Assets 86.32 million 96.83 million N/A 101.74 million 112.78 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 61.51 million N/A 81.75 million N/A 80.75 million
Short Term Investments 48.82 million 62.62 million N/A 74.22 million 62.33 million
Long Term Debt 16.59 million 16.5 million N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 5.39 million 2.01 million N/A 3.39 million 1.81 million

Exicure, Inc (XCUR) Chart:

Exicure, Inc (XCUR) News:

Below you will find a list of latest news for Exicure, Inc (XCUR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Exicure, Inc (XCUR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest XCUR Trades:

Date Shares Price
Jun 13, 2022 7:51 PM EST100$0.1263
Jun 13, 2022 7:52 PM EST200$0.1259
Jun 13, 2022 7:58 PM EST100$0.1253
Jun 13, 2022 7:59 PM EST26$0.1253
Jun 13, 2022 7:59 PM EST74$0.1253

Exicure, Inc (XCUR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000052/0001698530-20-000052-index.htm
2019-08-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1698530/000089581319000017/0000895813-19-000017-index.htm
2019-08-09SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1698530/000090571819000663/0000905718-19-000663-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000090571819000989/0000905718-19-000989-index.htm
2019-08-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1698530/000092963819000742/0000929638-19-000742-index.htm
2019-10-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1698530/000093583619000523/0000935836-19-000523-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1698530/000093583620000151/0000935836-20-000151-index.htm
2020-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120031317/0001209191-20-031317-index.htm
2020-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120034594/0001209191-20-034594-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120034595/0001209191-20-034595-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035121/0001209191-20-035121-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035122/0001209191-20-035122-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035123/0001209191-20-035123-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035124/0001209191-20-035124-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035126/0001209191-20-035126-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035127/0001209191-20-035127-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035128/0001209191-20-035128-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120035256/0001209191-20-035256-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120037163/0001209191-20-037163-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000120919120041770/0001209191-20-041770-index.htm
2020-02-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1698530/000153526420000002/0001535264-20-000002-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1698530/000153526420000003/0001535264-20-000003-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000109/0001698530-19-000109-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000111/0001698530-19-000111-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000113/0001698530-19-000113-index.htm
2019-08-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000116/0001698530-19-000116-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000118/0001698530-19-000118-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000120/0001698530-19-000120-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000123/0001698530-19-000123-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000125/0001698530-19-000125-index.htm
2019-08-09424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000128/0001698530-19-000128-index.htm
2019-08-09424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000130/0001698530-19-000130-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000133/0001698530-19-000133-index.htm
2019-09-2310-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000136/0001698530-19-000136-index.htm
2019-09-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000139/0001698530-19-000139-index.htm
2019-09-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000140/0001698530-19-000140-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000145/0001698530-19-000145-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000146/0001698530-19-000146-index.htm
2019-11-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000149/0001698530-19-000149-index.htm
2019-11-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000150/0001698530-19-000150-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000153/0001698530-19-000153-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000156/0001698530-19-000156-index.htm
2019-12-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000159/0001698530-19-000159-index.htm
2019-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1698530/000169853019000162/0001698530-19-000162-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853019000165/0001698530-19-000165-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000004/0001698530-20-000004-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000008/0001698530-20-000008-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1698530/000169853020000013/0001698530-20-000013-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000014/0001698530-20-000014-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000019/0001698530-20-000019-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000020/0001698530-20-000020-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000021/0001698530-20-000021-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000022/0001698530-20-000022-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000025/0001698530-20-000025-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000028/0001698530-20-000028-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000029/0001698530-20-000029-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000032/0001698530-20-000032-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1698530/000169853020000034/0001698530-20-000034-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000041/0001698530-20-000041-index.htm
2020-06-08POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000042/0001698530-20-000042-index.htm
2020-06-08POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000043/0001698530-20-000043-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000047/0001698530-20-000047-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000050/0001698530-20-000050-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000052/0001698530-20-000052-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000057/0001698530-20-000057-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1698530/000169853020000059/0001698530-20-000059-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000064/0001698530-20-000064-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000067/0001698530-20-000067-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1698530/000169853020000072/0001698530-20-000072-index.htm
2020-06-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1698530/999999999520001372/9999999995-20-001372-index.htm
2020-06-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1698530/999999999520001373/9999999995-20-001373-index.htm

Exicure, Inc (XCUR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Exicure, Inc (XCUR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2333%
Institutional Ownership: 4617%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-12AURASENSE LLC10% Share HolderSell10,195.002.8328,851.8511,257,629.00https://www.sec.gov/Archives/edgar/data/1698530/000169853020000052/0001698530-20-000052-index.htm
2020-06-12Chad A. MirkinDirectorSell10,195.002.8328,851.8511,257,629.00https://www.sec.gov/Archives/edgar/data/1698530/000120919120037163/0001209191-20-037163-index.htm
2020-03-12Chad A. MirkinDirectorBuy15,000.001.4521,750.0015,000.00https://www.sec.gov/Archives/edgar/data/1698530/000169853020000019/0001698530-20-000019-index.htm
2019-08-02DAVID R WALTDirectorBuy1,000,000.002.002,000,000.001,767,711.00https://www.sec.gov/Archives/edgar/data/1698530/000169853019000109/0001698530-19-000109-index.htm
2020-03-12DAVID S SNYDERChief Financial OfficerBuy18,248.001.4025,591.0018,248.00https://www.sec.gov/Archives/edgar/data/1698530/000169853020000020/0001698530-20-000020-index.htm
2020-03-13DAVID R WALTDirectorBuy291,066.001.21352,859.312,058,777.00https://www.sec.gov/Archives/edgar/data/1698530/000169853020000021/0001698530-20-000021-index.htm
2019-08-02Chad A. MirkinDirectorBuy25,000.002.0050,000.0025,000.00https://www.sec.gov/Archives/edgar/data/1698530/000169853019000113/0001698530-19-000113-index.htm
2019-08-02Jay VenkatesanDirectorBuy250,000.002.00500,000.00302,234.00https://www.sec.gov/Archives/edgar/data/1698530/000169853019000111/0001698530-19-000111-index.htm
2020-07-06Jay VenkatesanDirectorBuy9,310.000.656,051.50311,544.00https://www.sec.gov/Archives/edgar/data/1698530/000120919120041770/0001209191-20-041770-index.htm
2020-07-06Jay VenkatesanDirectorBuy12,930.001.0313,317.90324,473.00https://www.sec.gov/Archives/edgar/data/1698530/000120919120041770/0001209191-20-041770-index.htm
2020-05-20Chad A. MirkinDirectorBuy49,649.000.6532,271.8564,649.00https://www.sec.gov/Archives/edgar/data/1698530/000120919120031317/0001209191-20-031317-index.htm
2019-12-19Bali MuralidharDirectorBuy727,000.002.751,999,250.006,977,000.00https://www.sec.gov/Archives/edgar/data/1698530/000090571819000989/0000905718-19-000989-index.htm